Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Current Assets (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Current Assets for 12 consecutive years, with $8.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets fell 21.7% year-over-year to $8.4 million, compared with a TTM value of $8.4 million through Sep 2025, down 21.7%, and an annual FY2024 reading of $9.2 million, down 38.27% over the prior year.
  • Current Assets was $8.4 million for Q3 2025 at Arcadia Biosciences, up from $7.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $56.6 million in Q1 2021 and bottomed at $7.6 million in Q2 2025.
  • Average Current Assets over 5 years is $24.1 million, with a median of $23.3 million recorded in 2023.
  • The sharpest move saw Current Assets surged 138.29% in 2021, then plummeted 57.21% in 2024.
  • Year by year, Current Assets stood at $35.4 million in 2021, then dropped by 28.23% to $25.4 million in 2022, then plummeted by 41.05% to $15.0 million in 2023, then plummeted by 38.27% to $9.2 million in 2024, then fell by 9.25% to $8.4 million in 2025.
  • Business Quant data shows Current Assets for RKDA at $8.4 million in Q3 2025, $7.6 million in Q2 2025, and $8.8 million in Q1 2025.